These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1979900)

  • 21. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical effectiveness of KL 007 (oxybutynin hydrochloride) in urinary disorders].
    Takimoto Y; Kiyotaki S; Kawazoe K; Fuse T; Kitamura K; Yamamoto T; Satoh Y; Okada K; Kishimoto T
    Hinyokika Kiyo; 1985 Dec; 31(12):2284-301. PubMed ID: 3832931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic effect of Robaveron tablet (KN-7) on neurogenic bladder].
    Endo H; Sonoda T; Koyanagi T; Maru A; Kuroda K; Takamura T; Inada F; Rokuzyo M; Ohori T; Kubo T
    Hinyokika Kiyo; 1984 Jan; 30(1):135-44. PubMed ID: 6375318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
    Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
    J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experience in the use of propiverine hydrochloride (P-4) for patients suffering from urinary frequency and/or incontinence].
    Yokoyama O; Miyazaki K; Ishida T; Fujita Y; Hisazumi H
    Hinyokika Kiyo; 1990 Apr; 36(4):517-23. PubMed ID: 2378310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population.
    Kramer SA; Rathbun SR; Elkins D; Karnes RJ; Husmann DA
    J Urol; 2005 Jun; 173(6):2121-4; discussion 2124. PubMed ID: 15879863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical effect of terodiline hydrochloride (TD-758) in patients with urinary disturbances].
    Nakano M; Tajima A; Aso Y; Suzuki K; Hata M; Tsukada T; Masuda H; Hirose J; Kitagawa M; Nakahara M
    Hinyokika Kiyo; 1988 Jan; 34(1):196-200. PubMed ID: 3376801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of essential hypertension with the alpha-1 antagonist bunazosin retard. A multicenter, double-blind, placebo-controlled study].
    Kirsten R; Weidinger G
    Arzneimittelforschung; 1994 Jan; 44(1):13-6. PubMed ID: 7907871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
    Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
    Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.
    Low BY; Liong ML; Yuen KH; Chee C; Leong WS; Chong WL; Khan NA; Cheah PY; Liong KK
    J Urol; 2008 Apr; 179(4):1461-9. PubMed ID: 18295277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of tamsulosin on systemic blood pressure and nonneurogenic dysfunctional voiding in children.
    Vanderbrink BA; Gitlin J; Toro S; Palmer LS
    J Urol; 2009 Feb; 181(2):817-22; discussion 822. PubMed ID: 19110267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study].
    Jardin A
    Ann Urol (Paris); 1988; 22(5):333-40. PubMed ID: 2462402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.